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533Abstracts
preferably using time trade-off, by a representative
sample from the general public. For the GBD-1990, 
disability weights (DWs) were derived for disease-speciﬁc
health state descriptions from an expert panel using
person trade-off. QALY values and DWs, respectively, are
combined with life-years directly and may be discounted,
whereas DALYs additionally included age weights.
RESULTS: We argue that, though apparent, the various
valuation methods and respondent panels are not the
most important differences. The important novelty of
DALYs lies in the derivation of disease speciﬁc disability
weights. Disease labeling adds information to an 
otherwise generic health state description and may have
added to the validity of the weights, but also disclosed
critical problems with the assumed utility independence
of survival and quality of life. The standard QALY
approach of summing separately valued one-year periods
appeared not to work for diseases characterized by rapid
transitions through different health states. CONCLU-
SION: The problems with DALYs uncovered some impor-
tant limitations of the standard QALY approach. This
may have important methodological implications for the
evaluation of the effects of interventions for attack-type
and short duration diseases.
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OBJECTIVE: Assessing Treatment Satisfaction (TS) has
become an important outcome for many trials and may
be the critical health outcome for differentiating drugs,
which have equal efﬁcacy. Unfortunately, most TS mea-
sures have not been developed according to appropriate
methodology to ensure reliability and validity. Addition-
ally, as with QoL, the choice to use a generic versus
disease speciﬁc measures can be problematic. This paper
will present and illustrate a solution to this problem by
demonstrating how a generic conceptual framework for
TS can be adapted for a diabetes disease speciﬁc measure.
METHOD: Building on a generic model of TS with
domains of efﬁcacy, side effects, willingness to use/rec-
ommend, impact on daily life, mode of delivery and 
convenience, diabetes disease speciﬁc deﬁnitions of these
domains were derived from patient focus groups and
expert interviews. Existing diabetes TS measures were
examined and limitations were identiﬁed. RESULTS: The
process for developing a generic/disease speciﬁc TS
measure was identiﬁed. Based on this process, a new
disease speciﬁc TS measure, the TSDQ (Treatment 
Satisfaction Diabetes Questionnaire) was developed. The
TSDQ, because it is based on a generic TS conceptual
model, is methodologically sound as well as being con-
ceptually grounded. This paper will identify limitations
with current TS measures, outline the process for 
developing methodological sound generic/disease speciﬁc
TS measures and present the TSDQ development. CON-
CLUSION: Using a generic conceptual model to develop
disease speciﬁc TS measures can help resolve the dilemma
of whether to use a generic or a disease speciﬁc measure.
This hybrid methodology for TS instrument development
will facilitate the promotion of TS claims and help to
solidify the scientiﬁc integrity of TS outcomes.
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OBJECTIVE: A common perspective of health econo-
mists involves the use of QALYs to prioritize activities,
given equal costs. In this mode of thinking, an activity
that took N people from a bad state to healthy for X years
should have priority over an activity that took N other
people from a bad state to a moderate state of health for
X years. In addition to prioritizing based on expected
outcome of the activity, QALY-thinking requires the 
prioritizing of treatment of the young over the old and
the treatment of those with healthy lifestyles over those
with unhealthy lifestyles (both based on longer expected
life-spans). This study was designed to investigate
whether this was the view shared by the general public 
of the United States. METHODS: This was done by 
surveying a cross-spectrum of subjects—including 
physicians, nurses, health administrators, as well as non-
healthcare workers. The survey consisted of six cases in
which the respondent was asked to prioritize two patients
who had presented to the emergency department, both
with life-threatening conditions requiring immediate
intervention. RESULTS: While the number of subjects
leaves room for interpretation, it would appear that inde-
pendent of ﬁeld of work, education level, age or sex,
approximately 80 percent of study participants tended to
emphasize equality in value of life and fairness in receiv-
ing treatment rather than expected quantity or quality of
life-years after the treatment.
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OBJECTIVES: It has been argued that gain in health state
valuation after intervention is smaller from a patient 
perspective than from a nonpatient perspective. In this
study we use hearing impairment as a research model to
test whether illness experience, personal or through
medical experience, inﬂuences gain in health state valua-
